The UK NSC recommendation on Medium Chain Acyl CoA Dehydrogenase Deficiency (MCADD) screening in newborns (currently under review)
Find general information about population health screening.
More about MCADD
Fatty acids are one of the body's fuels: oxidation is the process by which they are broken down to release energy. This process has many steps, each catalysed by a different enzyme. Fatty acid oxidation (FAO) disorders result from deficiency of one of these enzymes.
MCADD is the commonest FAO disorder, affecting between 1 in 10,000 and 1 in 20,000 newborn babies.
Patients with MCADD deficiency are healthy most of the time. Infections or prolonged fasting, however, can lead to drowsiness and coma or sudden death. MCADD is treated through dietary management.
Further information about MCADD and its management can be found in the "Newborn screening for medium chain acyl CoA dehydrogenase deficiency" article, which can be downloaded from the 'related documents' section on this page.
Screening in the UK
Compare how screening is offered across the UK.
• British Dietetic Association
The stakeholder groups will be involved when the recommendation is next reviewed. If you think your organisation should be added, please contact us. More information for stakeholders can be found in appendix C of the UK NSC evidence review process.
Recommendation Review History
On 7 February 2007, the English Health Minister announced that all newborn babies in England are to be offered screening for MCADD by March 2009.
As of February 2009, all babies in England are offered screening for MCADD and a reception was held in March 2009 at the Houses of Parliament to launch this successful implementation. See the UCL Institute of Child Health press release.
The full report into prevalence, predictive value and test validity of screening for MCADD, based on 1.5 million babies, was published in 2011 and can be found here.
Related documentsMCADD Pilot Study Summary (PDF document, 119KB, 22/01/15)
More optionsGo to top